Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04119336 · ClinicalTrials.gov registry record · Phase 2
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
A Phase 2 study, sponsored by Andrew Yee, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04119336: Clinical Trial Phase 2 study, sponsored by Andrew Yee, MD.
NCT04119336 is a Phase 2 study that was terminated before completion, run by Andrew Yee, MD. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04119336, a Phase 2 study, was terminated before completion, sponsored by Andrew Yee, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Primary Outcome
ORR is defined as percentage of participants with complete response (CR) and partial response (PR) per International Myeloma Working Group (IMWG) criteria below. * CR = Negative immunofixation on serum and urine; disappearance of soft tissue plasmacytomas, and \<5% plasma cells in bone marrow * Stringent CR = Above definition plus normal FLC ration and absence of clonal cells in bone marrow by IHC or 2-4 color flow cytometry * PR = At least 50% reduction of serum M-protein and reduction in 24 u
Interventions
- DRUG Cyclophosphamide
- DRUG Nivolumab
- DRUG Dexamethasone
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-02-14 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 2 |
Why NCT04119336 stopped before completion
NCT04119336 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04119336 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04119336 about?
NCT04119336 is a clinical study titled "Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma". This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
What is the current status of trial NCT04119336?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-02-14. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT04119336?
The interventions under investigation include: Cyclophosphamide (DRUG), Nivolumab (DRUG), Dexamethasone (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT04119336?
This trial is sponsored by Andrew Yee, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04119336's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI